# Joint Nordic Procurement of Pharmaceuticals - 2025 - NF2.1301.a

- **Source:** TED · `376656-2025`
- **Buyer:** Amgros I/S
- **Published:** 2025-06-11
- **Deadline:** —
- **Estimated value:** 13,922,377 EUR
- **CPV codes:** 33600000
- **Place-of-performance NUTS:** DK011, DNK
- **Buyer-address NUTS:** —
- **Notice type:** can-standard / 29

## Procedure details

Source lists may span several lots; list positions do not establish relationships.

### Procedure Types

- open

### Award Criterion Descriptions

- Price is not the only award criterion and all criteria are stated only in the procurement documents.

### Options

- Clause 8.2 of the framework agreement provides for an option for delivery in a pre-agreement period (i.e. before the purchase period begins) and an option for delivery in a post-agreement period (i.e. after the purchase period). The two options may be exercised on the terms and conditions stipulated in the framework agreement. The estimated duration in section 5.1.3 is including the options for renewals. The framework agreements ordinary duration is from 1.4.2025 to 31.3.2027.

## Description

Denmark, Norway and Iceland have entered into cooperation regarding the procurement of pharmaceuticals. The countries will jointly procure and award framework agreements in order to ensure the supply of pharmaceuticals in the countries. In Denmark certain pharmaceuticals are resold to the Faroe Island and Greenland. Under this tender group, the pharmaceuticals are tendered under each lot no. for the purpose of supplying the Contracting Authorities as 2 markets (Norway as 1 market and Denmark and Iceland as 1 market) see the tender specification. The obligation to deliver the pharmaceuticals in Iceland is subject to the precondition that the supplier obtains an exemption regarding printed labels and leaflets. If the supplier does not obtain such exemption the agreement will only apply to Denmark and Norway, see the Framework agreement section 2.2.1 and Appendix 6.

## Award result

- **Published notice total:** 227,000,000 EUR
- **Contract concluded:** 2024-09-30
- **Winner:** FrostPharma AB (CVR 556814-1708), STADA Nordic ApS (CVR 13902992), EQL Pharma AB (CVR 556713-3425), Fresenius Kabi (CVR 21347809), Navamedic AB (CVR 556564-9661), B. Braun Medical AS (CVR 914 113 172), B. Braun Medical A/S (CVR 20343249), Hameln Pharma ApS (CVR 39720213), Orion Pharma A/S (CVR 20601116) · value 227,000,000 EUR
Published values may cover multiple lots, options and frameworks; they are not supplier revenue. Unlinked notice summaries do not assign each value or expiry to each winner.

## Original notice

https://ted.europa.eu/da/notice/-/detail/376656-2025